As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and opportunities
FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic communications environment.
Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.
Dan Chichester, chief creative officer, LLNS
When you have a successful brand, you tamper with it at your peril
We cemented our credibility during the most difficult period for publishing
Stuart Raetzman, CEO, Galderma Labs
Linzess has been enhanced and reworked to reach self-identified sufferers with its own brand relief story
What happens when it's the FDA—not a medical marketer—that is doing the overstating?
Don't waste another minute or dollar on your brand standards manual. It's painfully irrelevant
Pharma cites "payer pressure" as one of its biggest marketing challenges yet struggles to make the "value" case for products. How can it translate market-access awareness into reimbursement success?
More than 100 esteemed industry leaders and thinkers spent several hours discussing, reviewing and scoring around 700 entries to the MM&M Awards. Here are the results of their efforts—the 2014 finalists
Pharma is moving toward a broader treatment paradigm based on providing additional services for patients. Boris Kushkuley describes what the Pill+ model looks like, and how multichannel marketing can facilitate it
Immunotherapy is an emerging powerhouse in cancer treatment. Early gains being made in multiple tumor types provide a glimpse of the effectiveness of several agents and regimens. While longer follow-up is needed, the results have analysts talking about a big shift in the war on cancer. Joe Dysart reports
When assessing the value of breakthrough drugs, Health Economics & Outcomes Research can help generate the economic profile of a new therapy. Mohan Bala and Meghan Gallagher explain its use
A major information explosion is just the tip of the iceberg in the paradigm shift that is taking place between pharma, marketers and the patients that they serve. James Chase asks experts from across the patient-to-pharma spectrum how the industry can negotiate the new environment to successfully put patients first
Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports
Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.
What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?
A steady focus on data analytics brings a new level of relevance
At Chicago firm, new business and a new strategic partnership
Thinking globally leads this agency to continued solid performance
Bucking the "monolithic" model results in client, revenue growth
After 30 years in the business, still finding new avenues to explore
Chicago firm broadens its base beyond a rare-disease specialty
A focus on specialty pharma puts this agency in a solid position
Longtime "patient-centric" agency sets the engagement standard
Getting out of the "professional agency box" spurs major growth
Launch leaders: Agency excels at helping brands get to market
Changing technology opens a path to "business transformation"
Chicago firm leverages specialty expertise into growing revenues
Getting out of its comfort zone lets agency pursue new opportunities
New collaboration at the top invigorates inVentiv Health shop
Keeping an eye on the media mix while never losing sight of digital
An agency with a big name and clients takes a personal approach
Agency comes out swinging after Pfizer hit, and scores a comeback
A broader scope opens the path to a new set of opportunities
Tempering a diversification drive with a focus on the fundamentals
Understanding patient behavior helps this agency bring in clients
A nimble, flexible approach attracts a diversified client base
Change is a constant across the board for this Boston-based firm
Launches and orphan brands lead agency to its "best year ever"
Even a year filled with changes "didn't change who we were"
"Great growth, new clients, new work" at this McCann shop
A new leader aims to transform both his agency—and healthcare
Maintaining a culture that has brought about long-term success
Taking a different line of thought brings double-digit growth
A well-planned transition puts agency in "a place of strength"
Using a "full-circle" approach attracts a broad range of clients
Future-focused, "fiercely independent" Toronto agency continues to surge
Moving past the consolidation hurdle with expansion and strength
Solid knowledge of devices and diagnostics brings in business
Achieving success by creating unique experiences, not just ads
A hi-tech focus adds devices work to Toronto shop's roster
A David that can go toe-to-toe with the network-agency Goliaths
"Mobile is here to stay," and this agency is poised to benefit from it
Despite a six-month breather from pitches, ICC firm's sales rose
Acting like a conflict shop—with the resources of a large company
New talent and expanding scope have made it "a different agency"
A new parent company creates a better position for moving forward
Reimbursement is a hurdle, but HLG is succeeding nonetheless
Getting under the PHCG umbrella, but keeping its staff and culture
Despite a rocky year, agency sets a solid course for future success
By thinking locally, the agency develops global-scale success
Expertise in digital and devices nets record year for Austin agency
Employing a tech-forward strategy to create "a new kind of agency"
For this agency, it's not about saying "digital," it's about doing it
A setbacl from a major client opens a path to diversification
Experimentation is the key word at the Havas network software hub
Balancing the status quo with a taste for the new reaps benefits
A team that deftly fielded several curves the FDA threw its way
Digital is just a small part of this Havas agency's portfolio of skills
Network shop's nimble approach makes waves in the Boston market
With a major merger in the rearview mirror, focus is firmly on the future
Figuring out big data paves a pathway to large-scale growth
Betting on the value of senior-level talent pays off big for SF agency
Finding success by engaging in conversations about healthcare
A great work environment leads to great ideas and great work
At the center of a new network, agency has a solid, steady year
Digital chops power Omincom agency past client setbacks
A collaborative spirit has put this agency on the road to growth
A new name returns this agency to its roots and also moves it forward
Preparing for the future with a focus on evolution and efficiency
A relative newcomer makes its name in pharma and healthcare
Turning top talent and strong vision into increasing growth
More space, more locations and new leadership for a growing firm
Following up a smooth transition with a year of strong performance
Strategic and creative strengths result in an "outstanding" year
Creating strong momentum with a broad portfolio of services
Top on this agency's to-do list: establishing itself on a global scale
Bigger digs clear the way for roster expansion at suburban Philly firm
Medical device agency spreads its wings, but keeps core values
Expanding the healthcare playing field attracts clients and revenue
A team of new leaders pilots agency to its best year ever
Working on the front lines of the relationship-marketing revolution
Making social media a major player in brand communication
Keeping up with change sets agency up for continued success
Working effectively with clients results in wins—and awards
Living "Patients First" in a way that few other organizations do